CL2015000562A1 - Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta. - Google Patents

Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta.

Info

Publication number: CL2015000562A1
Authority: CL; Chile
Prior art keywords: polynucleotide; interest; plant; protoplasts; protoplast
Prior art date: 2012-09-07

Application number

CL2015000562A

Other languages

English (en)

Inventor

German Spangengerg

Sareena Sahab

John Mason

Original Assignee

Dow Agrosciences Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-07

Filing date

2015-03-06

Publication date

2015-06-12

2013-09-06 Priority claimed from US14/020,694 external-priority patent/US20140075593A1/en

2015-03-06 Application filed by Dow Agrosciences Llc filed Critical Dow Agrosciences Llc

2015-06-12 Publication of CL2015000562A1 publication Critical patent/CL2015000562A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

CL2015000562A 2012-09-07 2015-03-06 Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta. CL2015000562A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261697899P	2012-09-07	2012-09-07
US14/020,694 US20140075593A1 (en)	2012-09-07	2013-09-06	Fluorescence activated cell sorting (facs) enrichment to generate plants

Publications (1)

Publication Number	Publication Date
CL2015000562A1 true CL2015000562A1 (es)	2015-06-12

Family

ID=49170904

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2015000255A CL2015000255A1 (es)	2012-09-07	2015-02-03	Compuestos heterociclicos derivados de alcoxipirazoles, activadores de guanilato ciclasa soluble; composicion farmaceutica que los comprende; uso para tratar enfermedad cardiovascular, enfermedad renal, hiperplasia benigna de prostata, disfuncion erectil, enfermedad de alzheimer, enfermedad de parkinson, entre otras.
CL2015000562A CL2015000562A1 (es)	2012-09-07	2015-03-06	Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL2015000255A CL2015000255A1 (es)	2012-09-07	2015-02-03	Compuestos heterociclicos derivados de alcoxipirazoles, activadores de guanilato ciclasa soluble; composicion farmaceutica que los comprende; uso para tratar enfermedad cardiovascular, enfermedad renal, hiperplasia benigna de prostata, disfuncion erectil, enfermedad de alzheimer, enfermedad de parkinson, entre otras.

Country Status (37)

Country	Link
US (2)	US8906904B2 (es)
EP (1)	EP2892891B1 (es)
JP (1)	JP5970134B2 (es)
KR (1)	KR101692707B1 (es)
CN (1)	CN104619695B (es)
AP (1)	AP2015008231A0 (es)
AR (1)	AR092869A1 (es)
AU (1)	AU2013312931B2 (es)
BR (1)	BR112015004529B1 (es)
CA (1)	CA2880494C (es)
CL (2)	CL2015000255A1 (es)
CY (1)	CY1122610T1 (es)
DK (1)	DK2892891T3 (es)
EA (1)	EA027244B1 (es)
EC (1)	ECSP15012804A (es)
ES (1)	ES2748798T3 (es)
GE (1)	GEP20176631B (es)
HR (1)	HRP20191755T1 (es)
HU (1)	HUE046996T2 (es)
IL (1)	IL236987A (es)
LT (1)	LT2892891T (es)
MA (1)	MA37891B1 (es)
MD (1)	MD4425C1 (es)
MX (1)	MX338887B (es)
NZ (1)	NZ703989A (es)
PE (1)	PE20151001A1 (es)
PH (1)	PH12015500457A1 (es)
PL (1)	PL2892891T3 (es)
PT (1)	PT2892891T (es)
RS (1)	RS59394B1 (es)
SG (2)	SG10201510668UA (es)
SI (1)	SI2892891T1 (es)
TN (1)	TN2015000054A1 (es)
TW (1)	TWI586661B (es)
UA (1)	UA115881C2 (es)
UY (1)	UY35012A (es)
WO (1)	WO2014039434A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2013312931B2 (en) *	2012-09-07	2017-06-22	Boehringer Ingelheim International Gmbh	Alkoxy pyrazoles as soluble guanylate cyclase activators
TW201625584A (zh)	2014-07-02	2016-07-16	諾華公司	茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
JP6602840B2 (ja) *	2014-07-22	2019-11-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸
US10316020B2 (en)	2015-12-18	2019-06-11	Novartis Ag	Indane derivatives and the use thereof as soluble guanylate cyclase activators
EP3525778A1 (de)	2016-10-11	2019-08-21	Bayer Pharma Aktiengesellschaft	Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2019081456A1 (en)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en)	2017-12-15	2019-06-19	Bayer AG	The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
WO2019211081A1 (en)	2018-04-30	2019-11-07	Bayer Aktiengesellschaft	The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
JOP20200287A1 (ar)	2018-05-15	2020-11-09	Bayer Ag	بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
US11508483B2 (en)	2018-05-30	2022-11-22	Adverio Pharma Gmbh	Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
EP3820470B1 (en) *	2018-07-12	2024-09-11	Boehringer Ingelheim International GmbH	Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension
WO2020148379A1 (en)	2019-01-17	2020-07-23	Bayer Aktiengesellschaft	Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
PL3976591T3 (pl) *	2019-10-18	2023-07-31	Fmc Corporation	Sposoby wytwarzania kwasu 5-bromo-2-(3-chloropirydyn-2-ylo)-2h- pirazolo-3-karboksylowego
CN112079712B (zh) *	2020-09-18	2022-12-13	江苏美迪克化学品有限公司	一种对乙烯基水杨酸的制备方法
EP4011873A1 (en)	2020-12-10	2022-06-15	Bayer Aktiengesellschaft	Substituted pyrazolo piperidine carboxylic acids
WO2022122914A1 (en) *	2020-12-10	2022-06-16	Bayer Aktiengesellschaft	Substituted pyrazolo piperidine carboxylic acids
GB202102895D0 (en)	2021-03-01	2021-04-14	Cambridge Entpr Ltd	Novel compounds, compositions and therapeutic uses thereof
JP2025510685A (ja)	2022-03-21	2025-04-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	門脈圧亢進症を処置するための可溶性グアニル酸シクラーゼ活性化薬
JP2025518350A (ja)	2022-06-09	2025-06-12	バイエル・アクチエンゲゼルシヤフト	女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター
EP4611758A1 (en)	2022-11-04	2025-09-10	Boehringer Ingelheim International GmbH	Soluble guanylate cyclase activators for treating systemic sclerosis
EP4630113A1 (en)	2022-12-09	2025-10-15	Boehringer Ingelheim International GmbH	Solid forms of a sgc activator
WO2025036839A1 (en)	2023-08-16	2025-02-20	Boehringer Ingelheim International Gmbh	Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9824310D0 (en) *	1998-11-05	1998-12-30	Univ London	Activators of soluble guanylate cyclase
WO2002026712A2 (en)	2000-09-29	2002-04-04	Millennium Pharmaceuticals, Inc.	Quaternary amines and related inhibitors of factor xa
MXPA03004308A (es)	2000-11-22	2003-08-19	Visx Inc	Dispositivo de colocacion, accionado por la temperatura, para elementos opticos no lineales.
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
GB0212785D0 (en) *	2002-05-31	2002-07-10	Glaxo Group Ltd	Compounds
CA2509565A1 (en) *	2002-12-20	2004-07-15	Pharmacia Corporation	Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
US20100016305A1 (en)	2005-07-18	2010-01-21	Bayer Healthcare Ag	novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
WO2008021339A2 (en)	2006-08-15	2008-02-21	Wyeth	Pyrrolidine and related derivatives useful as pr modulators
MX2009011387A (es) *	2007-05-12	2009-11-09	Bayer Schering Pharma Ag	Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.
EA201070339A1 (ru) *	2007-09-06	2010-10-29	Мерк Шарп Энд Домэ Корп.	Активаторы растворимой гуанилатциклазы
WO2009043495A1 (en)	2007-10-05	2009-04-09	Sanofi-Aventis Deutschland Gmbh	Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en)	2007-11-30	2009-06-04	Smithkline Beecham Corporation	2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (es) *	2007-12-03	2009-07-17		Derivados de piridina activadores de guanilato ciclasa soluble
CA2720343A1 (en)	2008-04-04	2009-10-08	Takeda Pharmaceutical Company Limited	Heterocyclic derivative and use thereof
WO2010015652A2 (en) *	2008-08-07	2010-02-11	Smithkline Beecham Corporation	Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) *	2008-08-07	2010-02-11	Smithkline Beecham Corporation	Pyrimidine derivatives as activators of soluble guanylate cyclase
JP5501369B2 (ja)	2008-11-25	2014-05-21	メルク・シャープ・アンド・ドーム・コーポレーション	可溶性グアニレートシクラーゼ活性化剤
CN102316870A (zh) *	2009-01-17	2012-01-11	拜耳制药股份公司	sGC刺激剂或sGC活化剂联合PDE5抑制剂用于治疗勃起功能障碍
BRPI1008793A2 (pt)	2009-02-26	2016-03-08	Merck Sharp & Dohme	composto, uso de um composto, e, composição farmacêutica
WO2011095553A1 (en)	2010-02-05	2011-08-11	Bayer Schering Pharma Aktiengesellschaft	Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
KR101793304B1 (ko)	2010-02-05	2017-11-02	아드베리오 파마 게엠베하	낭성 섬유증의 치료를 위한, 단독으로의 및 ＰＤＥ5 억제제와 조합된 ｓＧＣ 자극제 또는 ｓＧＣ 활성화제
WO2011147810A1 (en) *	2010-05-26	2011-12-01	Bayer Pharma Aktiengesellschaft	THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
CA2803688A1 (en)	2010-06-25	2011-12-29	Bayer Intellectual Property Gmbh	Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
US8895583B2 (en)	2010-10-28	2014-11-25	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
EP2683710B1 (en)	2011-03-10	2017-07-19	Boehringer Ingelheim International GmbH	Soluble guanylate cyclase activators
WO2013025425A1 (en)	2011-08-12	2013-02-21	Boehringer Ingelheim International Gmbh	Soluble guanylate cyclase activators
EP2594270A3 (en)	2011-11-18	2013-07-31	BIP Patents	The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
AU2013312931B2 (en) *	2012-09-07	2017-06-22	Boehringer Ingelheim International Gmbh	Alkoxy pyrazoles as soluble guanylate cyclase activators

2013
- 2013-09-03 AU AU2013312931A patent/AU2013312931B2/en active Active
- 2013-09-03 EP EP13762666.9A patent/EP2892891B1/en active Active
- 2013-09-03 CA CA2880494A patent/CA2880494C/en active Active
- 2013-09-03 WO PCT/US2013/057826 patent/WO2014039434A1/en not_active Ceased
- 2013-09-03 EA EA201500298A patent/EA027244B1/ru not_active IP Right Cessation
- 2013-09-03 KR KR1020157005961A patent/KR101692707B1/ko active Active
- 2013-09-03 RS RSP20191306 patent/RS59394B1/sr unknown
- 2013-09-03 CN CN201380046266.3A patent/CN104619695B/zh active Active
- 2013-09-03 DK DK13762666.9T patent/DK2892891T3/da active
- 2013-09-03 JP JP2015531142A patent/JP5970134B2/ja active Active
- 2013-09-03 MX MX2015002807A patent/MX338887B/es active IP Right Grant
- 2013-09-03 PL PL13762666T patent/PL2892891T3/pl unknown
- 2013-09-03 HR HRP20191755TT patent/HRP20191755T1/hr unknown
- 2013-09-03 MD MDA20150019A patent/MD4425C1/ro active IP Right Grant
- 2013-09-03 BR BR112015004529-4A patent/BR112015004529B1/pt active IP Right Grant
- 2013-09-03 SG SG10201510668UA patent/SG10201510668UA/en unknown
- 2013-09-03 LT LTEP13762666.9T patent/LT2892891T/lt unknown
- 2013-09-03 MA MA37891A patent/MA37891B1/fr unknown
- 2013-09-03 SG SG11201500861QA patent/SG11201500861QA/en unknown
- 2013-09-03 NZ NZ703989A patent/NZ703989A/en unknown
- 2013-09-03 SI SI201331583T patent/SI2892891T1/sl unknown
- 2013-09-03 ES ES13762666T patent/ES2748798T3/es active Active
- 2013-09-03 GE GEAP201313783A patent/GEP20176631B/en unknown
- 2013-09-03 AP AP2015008231A patent/AP2015008231A0/xx unknown
- 2013-09-03 UA UAA201503030A patent/UA115881C2/uk unknown
- 2013-09-03 US US14/016,452 patent/US8906904B2/en not_active Ceased
- 2013-09-03 PT PT137626669T patent/PT2892891T/pt unknown
- 2013-09-03 HU HUE13762666A patent/HUE046996T2/hu unknown
- 2013-09-03 PE PE2015000295A patent/PE20151001A1/es active IP Right Grant
- 2013-09-06 UY UY0001035012A patent/UY35012A/es active IP Right Grant
- 2013-09-06 TW TW102132286A patent/TWI586661B/zh active
- 2013-09-06 AR ARP130103197A patent/AR092869A1/es active IP Right Grant
2015
- 2015-01-29 IL IL236987A patent/IL236987A/en active IP Right Grant
- 2015-02-03 CL CL2015000255A patent/CL2015000255A1/es unknown
- 2015-02-18 TN TNP2015000054A patent/TN2015000054A1/fr unknown
- 2015-03-03 PH PH12015500457A patent/PH12015500457A1/en unknown
- 2015-03-06 CL CL2015000562A patent/CL2015000562A1/es unknown
- 2015-04-02 EC ECIEPI201512804A patent/ECSP15012804A/es unknown
2016
- 2016-10-31 US US15/338,605 patent/USRE46886E1/en active Active
2019
- 2019-10-22 CY CY20191101099T patent/CY1122610T1/el unknown

Also Published As

Publication number	Publication date
HK1210164A1 (en)	2016-04-15
IL236987A (en)	2017-02-28
MA37891A1 (fr)	2018-01-31
PT2892891T (pt)	2019-11-05
BR112015004529B1 (pt)	2022-06-21
DK2892891T3 (da)	2019-10-14
EP2892891A1 (en)	2015-07-15
TWI586661B (zh)	2017-06-11
EP2892891B1 (en)	2019-07-31
TN2015000054A1 (en)	2016-06-29
TW201422607A (zh)	2014-06-16
AU2013312931A1 (en)	2015-02-05
PH12015500457B1 (en)	2015-04-20
PH12015500457A1 (en)	2015-04-20
MD4425B1 (ro)	2016-06-30
JP2015527394A (ja)	2015-09-17
BR112015004529A2 (pt)	2017-07-04
HUE046996T2 (hu)	2020-04-28
CN104619695A (zh)	2015-05-13
AR092869A1 (es)	2015-05-06
UY35012A (es)	2014-03-31
JP5970134B2 (ja)	2016-08-17
CA2880494A1 (en)	2014-03-13
BR112015004529A8 (pt)	2019-08-27
US20140073629A1 (en)	2014-03-13
NZ703989A (en)	2017-04-28
SG11201500861QA (en)	2015-04-29
US8906904B2 (en)	2014-12-09
PL2892891T3 (pl)	2020-01-31
AP2015008231A0 (en)	2015-01-31
MD4425C1 (ro)	2017-01-31
SI2892891T1 (sl)	2019-11-29
HRP20191755T1 (hr)	2019-12-27
SG10201510668UA (en)	2016-01-28
PE20151001A1 (es)	2015-07-15
CA2880494C (en)	2021-09-21
ES2748798T3 (es)	2020-03-18
CN104619695B (zh)	2018-04-10
KR101692707B1 (ko)	2017-01-04
MX338887B (es)	2016-05-04
AU2013312931B2 (en)	2017-06-22
USRE46886E1 (en)	2018-06-05
GEP20176631B (en)	2017-02-27
WO2014039434A1 (en)	2014-03-13
CL2015000255A1 (es)	2015-05-29
MD20150019A2 (ro)	2015-07-31
EA201500298A1 (ru)	2015-08-31
UA115881C2 (uk)	2018-01-10
ECSP15012804A (es)	2015-12-31
MA37891B1 (fr)	2018-05-31
MX2015002807A (es)	2015-05-15
EA027244B1 (ru)	2017-07-31
RS59394B1 (sr)	2019-11-29
KR20150048765A (ko)	2015-05-07
CY1122610T1 (el)	2021-03-12
LT2892891T (lt)	2020-01-27

Publication	Publication Date	Title
CL2015000562A1 (es)	2015-06-12	Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta.
MX367417B (es)	2019-08-21	Metodos de seleccion para microorganismos que imparten propiedades beneficiosas a las plantas.
MX2018004264A (es)	2018-11-09	Metodo para producir plantas completas a partir de protoplastos.
HK1218310A1 (zh)	2017-02-10	鉴定细胞群体、特别是间充质干细胞群体的多色流式细胞术方法
CL2017001873A1 (es)	2018-04-13	Métodos de purificación de cannabinoides, composiciones y kits de los mismos
GT201400265A (es)	2017-10-09	Composiciones y métodos para silenciar la expresión genética
MX357823B (es)	2018-07-25	Receptores del antígeno quimérico que seleccionan el antígeno para la maduración de las células b.
EP3161140A4 (en)	2017-12-20	Cannabichromenic acid synthase from cannabis sativa
EA201391602A1 (ru)	2014-04-30	Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
MX2019005692A (es)	2019-09-05	Procesos para producir lipidos.
ZA201501736B (en)	2016-10-26	Fluorescence activated cell sorting (facs) enrichment to generate plants
CL2014002235A1 (es)	2015-01-16	Proceso para la producción de gas de síntesis de amoníaco y una unidad inicial de una planta de amoníaco.
UY30621A1 (es)	2008-05-31	Método para la produccion de semilla de maiz hibrido y composiciones producidas a partir del mismo
GB201211142D0 (en)	2012-08-08	Microcapsules
AR088839A1 (es)	2014-07-10	Metodo para distribuir granos de polen
CL2012003449A1 (es)	2013-02-01	Procedimiento para aumentar la produccion de un yacimiento que comprende rocas las que contienen un mineral de sustancia valiosa que debe dejarse al descubierto por trituracion de las rocas, comprende realizacion de un proceso de perforacion por medio de un aparato de perforacion, creacion de un aerosol que comprende un polvo de perforacion.
BR112015004074A2 (pt)	2017-07-04	método para controlar pragas, uso e semente de uma planta cultivada.
CL2012002200A1 (es)	2013-10-18	Metodo para extraer cobalto del refinado que comprende proporcionar un suministro de refinado que comprende al menos cobalto, hierro, cobre, hierro y niquel, pre-tratar el refinado, remover sustancialmente todo el cobre del refinado con primera resina de intercambio ionico, absorber cobalto y niquel de segunda resina de intercambio ionico y eluir.
PH12014502791A1 (en)	2015-02-09	Methods for selection of introgression marker panels
AR081729A1 (es)	2012-10-17	Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades
CO6470817A2 (es)	2012-06-29	Cristales de solvato novedosos
PH12015500621A1 (en)	2015-05-11	Method for synthesising cyclohexenones and the use of same in the perfume industry
CO6331375A2 (es)	2011-10-20	Un proceso para la recuperacion de sulfuro metalico a partir de una solucion que contiene el ion del metal
UY33374A (es)	2011-12-30	Metodo para la extracción de material de una fruta de la familia sapindacea
PH12013502357A1 (en)	2014-01-06	Abe fermentation method comprising product absorption through isophoron